[go: up one dir, main page]

Latest News for: glp-1

Edit

MiSalud Health Partners with Anthropic to Offer All-Inclusive GLP-1 Support for $25\/month

News-Press Now 24 Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Feb 24, 2026-- .
Edit

MiSalud Health Partners with Anthropic to Offer All-Inclusive GLP-1 Support for $25/month

Times Argus 24 Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Feb 24, 2026-- ....
Edit

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut ...

CNBC 24 Feb 2026
The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs ... .
Edit

Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China

Watauga Democrat 24 Feb 2026
... a new–generation cAMP–biased GLP–1 receptor agonist.
Edit

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

Nasdaq Globe Newswire 24 Feb 2026
MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
Edit

US Pen Needles Market to Reach $1.53 Billion by 2031 as Diabetes Prevalence and GLP-1 ...

GetNews 24 Feb 2026
Growth is being driven by the expanding insulin-dependent population, broader adoption of injectable GLP-1 therapies, and the continued shift toward patient-centric, home-based diabetes management.
Edit

ShopRite offering freebies to those prescribed Ozempic, other GLP-1s

New Jersey Herald 24 Feb 2026
What to know about the side effects of GLP-1 drugs. With class action lawsuits filed, these are the alleged side effects of GLP-1 drugs, like Ozempic, Wegovy and Mounjaro ... The packs are complimentary when customers pick up their GLP-1 prescription.
Edit

Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1

PR Newswire 24 Feb 2026
Addressing a Critical Gap in the Obesity MarketDespite the significant clinical impact of GLP-1 receptor agonists, the majority of the more than 100 million American adults living with obesity remain untreated.
Edit

Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation

The Call 24 Feb 2026
On the other, the company is embroiled in a high-stakes regulatory storm, headlined by a newly disclosed investigation from the Securities and Exchange Commission (SEC) and a multi-front legal battle over its compounded GLP-1 weight-loss medications.
Edit

Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus

The Hill 24 Feb 2026
Novo Nordisk announced Tuesday it will be slashing the list price of ...
Edit

News24 | Weight loss jabs skyrocket in SA: Can generics make GLP-1s affordable by 2027?

News24 23 Feb 2026
The high cost of patented GLP-1s and absence of generics remain a major impediment to access in SA, where the medicines are unavailable in the public sector and often unaffordable ... .
Edit

Fancy clothes, mealtime alarms and Disney princess gigs: How GLP-1s are changing people's lives in ...

CNBC 23 Feb 2026
GLP-1 drugs for weight loss are growing in popularity in the U.S. and across the world. Here's what some users say about their experiences with the medicines ... .
Edit

Microdosing Ozempic: The Low-Dose GLP-1 Trend Explained

TimesDaily 23 Feb 2026
GLP-1 receptor agonists are widely used in metabolic ...
Edit

SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development (SureNano Science Ltd)

Public Technologies 23 Feb 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 129650477) .
Edit

Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push

Invezz 23 Feb 2026
Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart ... Lilly’s bigger bet is that the next phase of the GLP-1 boom won’t be won purely on clinical results. GLP-1 drugs are ...

Article Search

tools
×
×
×
×